Redirecting therapeutic T cells against myelin-specific T lymphocytes using a humanized myelin basic protein-HLA-DR2-zeta chimeric receptor.
Therapies that Ag-specifically target pathologic T lymphocytes responsible for multiple sclerosis (MS) and other autoimmune diseases would be expected to have improved therapeutic indices compared with Ag-nonspecific therapies. We have developed a cellular immunotherapy that uses chimeric receptors...
主要な著者: | Moisini, I, Nguyen, P, Fugger, L, Geiger, T |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
2008
|
類似資料
-
Efficient presentation of myelin oligodendrocyte glycoprotein peptides but not protein by astrocytes from HLA-DR2 and HLA-DR4 transgenic mice.
著者:: Kort, J, 等
出版事項: (2006) -
Synthetic peptides that inhibit binding of the myelin basic protein 85-99 epitope to multiple sclerosis-associated HLA-DR2 molecules and MBP-specific T-cell responses.
著者:: Fridkis-Hareli, M, 等
出版事項: (2001) -
Microfiber platform for oligodendrocyte myelination
著者:: Ong, William
出版事項: (2020) -
Myelin oligodendrocyte glycoprotein-35-55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2-transgenic mice.
著者:: Rich, C, 等
出版事項: (2004) -
Investigating the role of microglia in myelin development
著者:: Li, Liang
出版事項: (2021)